Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs BIO-TECHNE Corp — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $32.7, while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, MicroSectors FANG and Innovation 3X Leveraged ETN nearer its low. Which is the better fit depends on your goals.
| FNGU | TECH | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $36.15 | $72.29 |
52-Week Low | $13.73 | $43.31 |
Market Cap | — | $11.24B |
Enterprise Value | — | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a leveraged ETN tracking the FANG+ Index, trades at $33.53, up 4.65% today. Technical indicators show a bullish trend with strong moving average support, though the 6-day RSI at 94.67 signals overbought conditions. Recent news highlights extreme volatility, with a 16% intraday drop reported on June 5, 2026, underscoring the inherent risks of leveraged products.
The outlook remains highly speculative, driven by tech sector momentum but tempered by structural decay risks from daily rebalancing. Key risks include amplified losses during market downturns and the product's design, which can erode value over time. Investors should weigh the potential for high returns against the possibility of rapid capital depletion.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
